Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

Dutasteride may help reduce brain inflammation and improve cognition.

N-acetylcysteine and ImuVert can prevent hair loss in rats caused by chemotherapy.

The combination of encorafenib and binimetinib caused few skin issues.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.

Sonidegib and vismodegib have different side effects and reporting patterns.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A new therapy for a skin blistering condition has not been developed yet.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

SH-340 may improve skin barrier and help treat atopic dermatitis.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

A new topical treatment for hair loss shows promise by targeting androgen receptors.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Scientists created cell lines to study a genetic skin disorder using CRISPR technology.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.